ReviewBiochimica et biophysica acta. Molecular basis of disease2017
Epigenetic dysfunctional diseases and therapy for infection and inflammation.
Review in Biochimica et biophysica acta. Molecular basis of disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- The Future of Epigenetics: Emerging Technologies and Clinical Applications.ACS pharmacology & translational science · 2026Review
- Deciphering epigenetic regulation in cardiac developmental toxicity: Mechanisms and implications (Review).Molecular medicine reports · 2026Review
- Epigenetic regulation in early embryogenesis: mechanisms, developmental programming, and transgenerational implications.Frontiers in cell and developmental biology · 2026Review
- Phytochemicals as Epigenetic Modulators in Chronic Diseases: Molecular Mechanisms.Molecules (Basel, Switzerland) · 2025Review
- The pathway of autophagy in the epigenetic landscape ofAutophagy · 2025Review
- Development and Evaluation of [ACS omega · 2024Article
- Tunable DNMT1 degradation reveals DNMT1/DNMT3B synergy in DNA methylation and genome organization.The Journal of cell biology · 2024Article
- Targeting epigenetic regulators for inflammation: Mechanisms and intervention therapy.MedComm · 2022Review
- Effects of Donor Cell Types on the Development of Bovine Embryos Using Cytoplasm Injection Cloning Technology.International journal of molecular sciences · 2021Article
- Discovery of a Positron Emission Tomography Radiotracer Selectively Targeting the BD1 Bromodomains of BET Proteins.ACS medicinal chemistry letters · 2021Article
- Infectious Keratitis: An Update on Role of Epigenetics.Frontiers in immunology · 2021Review
- Gene expression signatures identify paediatric patients with multiple organ dysfunction who require advanced life support in the intensive care unit.EBioMedicine · 2020Article
- Inhibition of HDAC Enzymes Contributes to Differential Expression of Pro-Inflammatory Proteins in the TLR-4 Signaling Cascade.International journal of molecular sciences · 2020Article
- Uncovering epigenetic landscape: a new path for biomarkers identification and drug development.Molecular biology reports · 2020Review
- Activation of death-associated protein kinase 1 promotes neutrophil apoptosis to accelerate inflammatory resolution in acute respiratory distress syndrome.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- Epigenetic Changes in the Pathogenesis of Rheumatoid Arthritis.Frontiers in genetics · 2019Review
- Repetitive Element DNA Methylation is Associated with Menopausal Age.Aging and disease · 2018Article
- Early Disruption of the Microbiome Leading to Decreased Antioxidant Capacity and Epigenetic Changes: Implications for the Rise in Autism.Frontiers in cellular neuroscience · 2018Review
- The identification and validation of Trichosstatin A as a potential inhibitor of colon tumorigenesis and colon cancer stem-like cells.American journal of cancer research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Even though the discovery of the term 'epigenetics' was in the 1940s, it has recently become one of the most promising and expanding fields to unravel the gene expression pattern in several diseases. The most well studied example is cancer, but other diseases like metabolic disorders, autism, or inflammation-associated diseases such as lung injury, autoimmune disease, asthma, and type-2 diabetes display aberrant gene expression and epigenetic regulation during their occurrence. The change in the epigenetic pattern of a gene may also alter gene function because of a change in the DNA status. Constant environmental pressure, lifestyle, as well as food habits are the other important parameters responsible for transgenerational inheritance of epigenetic traits. Discovery of epigenetic modifiers targeting DNA methylation and histone deacetylation enzymes could be an alternative source to treat or manipulate the pathogenesis of diseases. Particularly, the combination of epigenetic drugs such as 5-aza-2-deoxycytidine (Aza) and trichostatin A (TSA) are well studied to reduce inflammation in an acute lung injury model. It is important to understand the epigenetic machinery and the function of its components in specific diseases to develop targeted epigenetic therapy. Moreover, it is equally critical to know the specific inhibitors other than the widely used pan inhibitors in clinical trials and explore their roles in regulating specific genes in a more defined way during infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.